Mesoblast Acquires Culture Expanded Stem Cell Therapeutic Business from Osiris – Benzinga
|
Mesoblast Acquires Culture Expanded Stem Cell Therapeutic Business from Osiris
Benzinga Mesoblast Limited (OTC: MBLTY) today announced the acquisition of the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics (NASDAQ: OSIR) by the Mesoblast Group. “The many commercial and strategic benefits of this … |
